Mirai Bio Expands Leadership Team to Scale the Integrated Delivery Engine Powering the Next Generation of Nucleic Acid Medicines

Summary

Mirai Bio announced Kate Torchilin as Chief Executive Officer and President, transitioning from interim CEO since November 2025, while maintaining a CEO-Partner role at Flagship Pioneering. The company develops an integrated delivery platform for nucleic acid medicines combining proprietary in vivo data, machine learning, and modular LNP design.